Frequent Aspirin Use Tied to Lower Ovarian Cancer Risk
Association remains regardless of the presence of most other risk factors for ovarian cancer
Gynecologic Cancers
HPV Vaccination May Cut Risk for CIN2+ Recurrence
Effect estimate stronger for CIN2+ for disease related to HPV subtypes HPV 16 or HPV 18
Tafinlar-Mekinist Combo Wins Tumor-Agnostic Indication for BRAF V600E Solid Tumors
The accelerated approval was based on data from two phase 2 trials: the ROAR basket study and the NCI-MATCH Subprotocol H study.
Mirvetuximab Soravtansine Granted Priority Review for Ovarian Cancer
Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.
Bevacizumab Biosimilar Alymsys Gets FDA Approval
The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.
Keytruda Approved for MSI-H/dMMR Advanced Endometrial Carcinoma
The approval was based on data from cohorts D and K of the phase 2 KEYNOTE-158 trial, which included patients with multiple types of advanced solid tumors.
Cemiplimab Application for Advanced Cervical Cancer Withdrawn
The decision was made to withdraw the application after the Companies and the FDA were not able to align on certain postmarketing studies.
Cervical Cancer Deaths Down Following HPV Vaccine Introduction
Reductions in cervical cancer incidence, mortality in the U.S. greater for those aged 15 to 24 years than those aged 25 to 29, 30 to 39 years
Cytalux Approved to Detect Ovarian Cancer Lesions During Surgery
Cytalux is a fluorescent drug intended to assist surgeons in identifying ovarian cancer lesions.
Oral WEE1 Inhibitor Gets Fast Track Status for Uterine Serous Carcinoma
ZN-c3 is a potential first-in-class inhibitor of WEE1, a DNA damage response protein, designed to generate sufficient DNA damage in cancer cells causing cell death.
